Literature DB >> 9833855

Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.

J Kubar1, P Marty, A Lelièvre, J F Quaranta, P Staccini, C Caroli-Bosc, Y Le Fichoux.   

Abstract

OBJECTIVE: To discriminate cases of visceral leishmaniosis (VL) following a primary infection from cases originating in a reactivation of a latent Leishmania infection and to assess the impact of CD4+ T-cell counts on the occurrence of VL in patients with HIV disease.
METHODS: We searched by Western blotting for the presence of Leishmania infantum-specific antibodies in the sera of 236 HIV-positive patients. We performed a follow-up of antileishmanial serology and analysed the evolution of the CD4+ T-cell counts for 14 HIV-positive VL patients and for 18 HIV-positive Leishmania-seropositive patients without VL.
RESULTS: This study (1) showed that the VL disease/Leishmania infection ratio in HIV-positive individuals is high (1 : 10); (2) discriminated between a primary Leishmania infection (five patients who converted from Leishmania-seronegative to Leishmania-seropositive) and a reactivation of a latent infection (seven patients); (3) showed that HIV-positive individuals with dramatically low CD4+ T-cell counts maintained or generated a specific antileishmanial antibody production; (4) demonstrated that the primary-VL appeared at significantly higher (P = 0.028) CD4+ T-cell levels than the reactivation-VL; (5) documented the existence of HIV-positive Leishmania-seropositive individuals who despite a severe and prolonged immunosuppression did not develop VL (eight of 18).
CONCLUSION: Our data stress the utility of the follow-up by Western blotting for an early diagnosis of VL, and therefore an early treatment, for HIV-positive patients living in endemic areas. They suggest that in a latent Leishmania infection supplementary control mechanism(s) might operate in addition to the T-cell-mediated response, and provide a further example of non-appearance of an opportunistic infection despite a severe reduction in CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9833855     DOI: 10.1097/00002030-199816000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Opsonization modulates Rac-1 activation during cell entry by Leishmania amazonensis.

Authors:  J Morehead; I Coppens; N W Andrews
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

2.  A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis.

Authors:  I Suffia; B Ferrua; X Stien; B Mograbi; P Marty; D Rousseau; K Fragaki; J Kubar
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

4.  Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq.

Authors:  Rupal M Mody; Ines Lakhal-Naouar; Jeffrey E Sherwood; Nancy L Koles; Dutchabong Shaw; Daniel P Bigley; Edgie-Mark A Co; Nathanial K Copeland; Linda L Jagodzinski; Rami M Mukbel; Rebecca A Smiley; Robert C Duncan; Shaden Kamhawi; Selma M B Jeronimo; Robert F DeFraites; Naomi E Aronson
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

5.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

6.  Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008).

Authors:  Ruth Gil-Prieto; Stefan Walter; Jorge Alvar; Angel Gil de Miguel
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

Review 7.  Leishmaniasis: new insights from an old and neglected disease.

Authors:  S Antinori; L Schifanella; M Corbellino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

8.  Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France.

Authors:  Y le Fichoux; J F Quaranta; J P Aufeuvre; A Lelievre; P Marty; I Suffia; D Rousseau; J Kubar
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

9.  Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis.

Authors:  Simona Bossolasco; Giovanni Gaiera; Davide Olchini; Maurizio Gulletta; Leonardo Martello; Arabella Bestetti; Laura Bossi; Luca Germagnoli; Adriano Lazzarin; Caterina Uberti-Foppa; Paola Cinque
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

10.  Leishmania major infection in a patient with visceral leishmaniasis: treatment with Amphotericin B.

Authors:  Mehdi Karamian; Mohammad Hossein Motazedian; Davood Mehrabani; Khodakaram Gholami
Journal:  Parasitol Res       Date:  2007-07-22       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.